I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination…
I-Mab, a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer,…
Read More...
Read More...